Profund Advisors LLC Inhibrx, Inc. Transaction History

Profund Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$32.76 - $39.56 $465,552 - $562,187	14,211 Added 82.99%	31,335 $1.1 Million
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $38,019 - $99,636	-2,622 Reduced 13.28%	17,124 $650,000
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $69,441 - $116,000	-4,409 Reduced 18.25%	19,746 $362,000
Q2 2023 Aug 10, 2023	SELL	$16.96 - $27.82 $78,762 - $129,196	-4,644 Reduced 16.13%	24,155 $627,000
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $531,341 - $781,604	28,799 New	28,799 $543,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Profund Advisors LLC with notifications on news.